Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Institutes of Health Clinical Center (CC)
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
BioNTech SE
All India Institute of Medical Sciences
National Cancer Institute (NCI)
National Cancer Institute (NCI)
NRG Oncology
NRG Oncology
NRG Oncology
Inhibrx Biosciences, Inc
West China Hospital
Bicara Therapeutics
University of Erlangen-Nürnberg Medical School
Cancer Research UK
South Egypt Cancer Institute
National Cancer Institute (NCI)
The Netherlands Cancer Institute
RenJi Hospital
Cancer Research UK
Cancer Research UK
Stanford University
Exelixis
University of British Columbia
Hookipa Biotech GmbH
Privo Technologies
Nantes University Hospital